Jean Pierre Schatzmann Peron
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 7 | 2022 | 38 | 1.790 |
Why?
|
| Zika Virus | 7 | 2022 | 37 | 1.750 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 5 | 2021 | 59 | 1.420 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2021 | 39 | 0.850 |
Why?
|
| Brain Diseases | 1 | 2023 | 75 | 0.730 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2021 | 7 | 0.690 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 107 | 0.620 |
Why?
|
| Microcephaly | 3 | 2022 | 15 | 0.560 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 45 | 0.480 |
Why?
|
| MicroRNAs | 2 | 2022 | 709 | 0.450 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 205 | 0.390 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 218 | 0.380 |
Why?
|
| Nervous System Malformations | 1 | 2022 | 12 | 0.380 |
Why?
|
| Virus Replication | 3 | 2021 | 322 | 0.380 |
Why?
|
| Endometrium | 2 | 2021 | 31 | 0.360 |
Why?
|
| Viral Vaccines | 2 | 2016 | 56 | 0.350 |
Why?
|
| Interleukin-17 | 3 | 2010 | 99 | 0.350 |
Why?
|
| Mitochondrial Dynamics | 1 | 2021 | 10 | 0.340 |
Why?
|
| Neuroimmunomodulation | 1 | 2021 | 7 | 0.340 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2020 | 4 | 0.320 |
Why?
|
| Antibody Formation | 1 | 2020 | 110 | 0.310 |
Why?
|
| Brain | 3 | 2023 | 1594 | 0.310 |
Why?
|
| Animals | 16 | 2022 | 21259 | 0.300 |
Why?
|
| Immune Tolerance | 2 | 2010 | 181 | 0.290 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 151 | 0.290 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.280 |
Why?
|
| Inflammation | 3 | 2021 | 1186 | 0.260 |
Why?
|
| Mitochondria | 1 | 2021 | 401 | 0.260 |
Why?
|
| Interleukin-10 | 3 | 2021 | 164 | 0.250 |
Why?
|
| Central Nervous System | 2 | 2021 | 200 | 0.240 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1004 | 0.230 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2010 | 112 | 0.220 |
Why?
|
| Mice | 8 | 2021 | 11070 | 0.220 |
Why?
|
| Placenta | 2 | 2021 | 68 | 0.200 |
Why?
|
| Lymphocyte Activation | 3 | 2021 | 752 | 0.190 |
Why?
|
| Pregnancy | 3 | 2022 | 2365 | 0.180 |
Why?
|
| Neuromyelitis Optica | 1 | 2021 | 12 | 0.180 |
Why?
|
| Vaccines, DNA | 2 | 2016 | 98 | 0.170 |
Why?
|
| Humans | 15 | 2023 | 64818 | 0.170 |
Why?
|
| Immunity | 2 | 2022 | 107 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 3467 | 0.160 |
Why?
|
| Female | 10 | 2022 | 33854 | 0.160 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2020 | 16 | 0.160 |
Why?
|
| Lymphocyte Depletion | 1 | 2010 | 96 | 0.160 |
Why?
|
| Allergens | 1 | 2010 | 54 | 0.160 |
Why?
|
| Immunity, Mucosal | 1 | 2009 | 53 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 226 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 2 | 2009 | 181 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 428 | 0.130 |
Why?
|
| Intestines | 1 | 2009 | 178 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2009 | 239 | 0.130 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2016 | 20 | 0.120 |
Why?
|
| Brazil | 3 | 2016 | 102 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2007 | 219 | 0.110 |
Why?
|
| Lung | 1 | 2020 | 962 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 2278 | 0.100 |
Why?
|
| Mosquito Vectors | 1 | 2022 | 17 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2022 | 50 | 0.090 |
Why?
|
| Vaccines, Inactivated | 2 | 2016 | 14 | 0.090 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 145 | 0.090 |
Why?
|
| Fallopian Tubes | 1 | 2021 | 13 | 0.090 |
Why?
|
| Viral Envelope Proteins | 2 | 2016 | 101 | 0.090 |
Why?
|
| Alarmins | 1 | 2021 | 4 | 0.090 |
Why?
|
| Interleukin-4 | 1 | 2021 | 147 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 669 | 0.080 |
Why?
|
| Cell Death | 1 | 2022 | 289 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2021 | 68 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 160 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 325 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 179 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2022 | 321 | 0.080 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 7 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2020 | 373 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2010 | 371 | 0.070 |
Why?
|
| Cytokines | 1 | 2021 | 951 | 0.060 |
Why?
|
| Vaccines, Subunit | 1 | 2016 | 40 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2016 | 102 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2016 | 310 | 0.060 |
Why?
|
| Biomarkers | 1 | 2020 | 1472 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 217 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 464 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1380 | 0.050 |
Why?
|
| Ketoglutaric Acids | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2183 | 0.050 |
Why?
|
| Pyruvates | 1 | 2022 | 3 | 0.050 |
Why?
|
| Mesocricetus | 1 | 2022 | 92 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 636 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2012 | 61 | 0.050 |
Why?
|
| Interleukins | 1 | 2012 | 86 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 52 | 0.050 |
Why?
|
| Glutamine | 1 | 2022 | 50 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 131 | 0.040 |
Why?
|
| Cricetinae | 1 | 2022 | 361 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2012 | 171 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 673 | 0.040 |
Why?
|
| Astrocytes | 1 | 2022 | 122 | 0.040 |
Why?
|
| Adipogenesis | 1 | 2012 | 81 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2012 | 342 | 0.040 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2010 | 9 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 28 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 81 | 0.040 |
Why?
|
| Systems Biology | 1 | 2020 | 36 | 0.040 |
Why?
|
| Epigenomics | 1 | 2020 | 62 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 106 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 654 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 83 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 476 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2020 | 246 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 852 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2010 | 189 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 373 | 0.040 |
Why?
|
| Phenotype | 1 | 2012 | 1231 | 0.040 |
Why?
|
| Antigens | 1 | 2009 | 145 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2010 | 415 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 380 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1134 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1589 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1112 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1979 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 395 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 74 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2016 | 21 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2016 | 137 | 0.030 |
Why?
|
| Organoids | 1 | 2016 | 41 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2016 | 130 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 47 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2009 | 531 | 0.030 |
Why?
|
| Fetus | 1 | 2016 | 101 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 260 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1555 | 0.030 |
Why?
|
| Hypertension | 1 | 2020 | 608 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 869 | 0.030 |
Why?
|
| Adult | 1 | 2021 | 17271 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 14879 | 0.030 |
Why?
|
| Male | 3 | 2020 | 30880 | 0.030 |
Why?
|
| Autophagy | 1 | 2016 | 231 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 703 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1034 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1095 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2016 | 912 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2009 | 279 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 574 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1286 | 0.010 |
Why?
|